Home > Haematology > EHA 2021 > Leukaemia > ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib

ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib

Presented By
Prof. Peter Hillmen, St James’s University Hospital, UK
Conference
EHA 2021
Trial
Phase 3, ELEVATE-RR
The phase 3, head-to-head ELEVATE-RR trial compared acalabrutinib versus ibrutinib in previously treated patients with chronic lymphocytic leukaemia (CLL). The first results indicate that acalabrutinib achieved better tolerability with fewer patients experiencing cardiovascular toxicities. Moreover, acalabrutinib had similar efficacy to ibrutinib. Ibrutinib was the first irreversible Bruton’s tyrosine kinase (BTK) inhibitor but has been associated with adverse events (AEs), particularly cardiovascular toxicities, that can lead to treatment discontinuation. Acalabrutinib is a next-generation, more selective BTK inhibitor. Prof. Peter Hillmen (St James’s University Hospital, UK) reported the first safety outcomes results of the randomised, multicentre, open-label ELEVATE-RR trial (NCT02477696), which compared safety and e...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on